Investor Relations

Corporate Profile

Tyme Inc. is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have tolerable toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic requirements to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s immune system.

News Releases

Events & Presentations

Upcoming Events

Corporate Fact Sheet

Stock Info

Quarterly Results

Corporate Governance Documents